UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest reported) December 10, 2002
Advanced Biotherapy, Inc.
| Delaware | 0-26323 | 95-0402415 | ||
|
|
||||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| 6355 Topanga
Canyon Boulevard, Suite 510 Woodland Hills, California |
91367 |
|
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (818) 883-6716
| Item 5. OTHER EVENTS. | ||||||||
| Item 7. FINANCIAL STATEMENTS AND EXHIBITS | ||||||||
| Signatures | ||||||||
| Ex-99.1 | ||||||||
Item 5. OTHER EVENTS.
The registrant published a press release on December 9, 2002, which reported that Advanced Biotherapy, Inc. has met with the United States Food and Drug Administration (FDA) and discussed the pathway and additional efforts needed to submit an Investigational New Drug Application (IND) to conduct Phase I clinical trials to treat corneal transplant rejection with antibodies to gamma interferon.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
| Designation | Description of Exhibit | |||
99.1 |
Press Release, dated December 9, 2002 | |||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ADVANCED BIOTHERAPY, INC. (Registrant) |
||||
| Date: December 10, 2002 | By: | /s/Edmond Buccellato Edmond Buccellato, President and CEO |
||
INDEX TO EXHIBITS
| Exhibit | Description | |||
99.1 |
Text of Press Release, dated December 9, 2002 | |||